Dr. Pietrantonio on Nomogram to Predict Survival Rates in CRC

Filippo Pietrantonio, MD
Published: Tuesday, Jul 19, 2016


Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that is used to predict 12-week survival rates for patients with colorectal cancer (CRC).

Pietrantonio explains that the nomogram can be utilized to identify patients with CRC who are at higher risk for death within 12 weeks.

Additionally, the nomogram can be used as a prognostication method for patient selection, as some of these high-risk patients are enrolled on clinical trials.

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that is used to predict 12-week survival rates for patients with colorectal cancer (CRC).

Pietrantonio explains that the nomogram can be utilized to identify patients with CRC who are at higher risk for death within 12 weeks.

Additionally, the nomogram can be used as a prognostication method for patient selection, as some of these high-risk patients are enrolled on clinical trials.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x